Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.
Hageman SHJ, Kaptoge S, de Vries TI, Lu W, Kist JM, van Os HJA, Numans ME, Läll K, Bobak M, Pikhart H, Kubinova R, Malyutina S, Pająk A, Tamosiunas A, Erbel R, Stang A, Schmidt B, Schramm S, Bolton TR, Spackman S, Bakker SJL, Blaha M, Boer JMA, Bonnefond A, Brenner H, Brunner EJ, Cook NR, Davidson K, Dennison E, Donfrancesco C, Dörr M, Floyd JS, Ford I, Fu M, Gansevoort RT, Giampaoli S, Gillum RF, Gómez-de-la-Cámara A, Håheim LL, Hansson PO, Harms P, Humphries SE, Ikram MK, Jukema JW, Kavousi M, Kiechl S, Kucharska-Newton A, Pablos DL, Matsushita K, Meyer HE, Moons KGM, Mortensen MB, Muilwijk M, Nordestgaard BG, Packard C, Pamieri L, Panagiotakos D, Peters A, Potier L, Providencia R, Psaty BM, Ridker PM, Rodriguez B, Rosengren A, Sattar N, Schöttker B, Schwartz JE, Shea S, Shipley MJ, Sofat R, Thorand B, Verschuren WMM, Völzke H, Wareham NJ, Westbury L, Willeit P, Zhou B, Danesh J, Visseren FLJ, Di Angelantonio E, Pennells L, Dorresteijn JAN.
Hageman SHJ, et al. Among authors: schwartz je.
Eur J Prev Cardiol. 2024 Oct 10;31(14):1690-1699. doi: 10.1093/eurjpc/zwae174.
Eur J Prev Cardiol. 2024.
PMID: 38752762
Free PMC article.
